March 2013

Recently, we noted a pay-to-play scandal in Pennsylvania that resulted in multiple arrests.  This week, New Jersey’s Attorney General charged seven executives or shareholders of Birdsall Services Group, an engineering firm.  The alleged Birdsall scheme illustrates the ease with which pay-to-play violations and campaign finance violations can mix.

Pay-to-play laws typically restrict or prohibit public

With near-unanimous bipartisan majorities, Congress last year passed the Stop Trading on Congressional Knowledge (“STOCK”) Act in an effort to confront alleged insider trading by federal officials.  A major part of that legislation required that financial information of high-level government employees be disclosed in a searchable, sortable, and downloadable internet database.  Although the officials’ underlying

The public-facing portion of the FCC’s online public inspection file system for broadcast TV stations apparently was unavailable for part of the day on Wednesday. Although the outage was fairly brief — we first saw the error below late in the morning, and we could access the system again by mid-afternoon — it is a reminder that

The Affordable Care Act has numerous provisions that restrict the amounts that employer-sponsored health plans may require employees to pay for health care.  These provisions include prohibitions on annual and lifetime dollar limits on essential health benefits, restrictions on out-of-pocket maximums, and requirements to provide preventive care services and items at no cost to participants. 

The times when private antitrust damages claims were not a serious risk in the European Union are gone.  The European Commission and national competition authorities are actively promoting follow-on damages claims by private plaintiffs, and national health authorities are themselves bringing huge claims for damages arising from anticompetitive practices.

The following are examples of recent

In February 2013, the French Competition Authority (“FCA”) launched an inquiry into the pharmaceutical sector, examining each level of the medicinal distribution chain (pharmaceutical suppliers, wholesalers and retailers).  The FCA is likely to focus on a broad range of issues, including:

  • Generic entry: The inquiry will likely examine pay-for-delay arrangements and other issues relating